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Collagens are extracellular matrix (ECM) proteins that sup-
port the structural and biomechanical integrity of many tissues.
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2)
encodes the only lysyl hydroxylase (LH) isoform that specifically
hydroxylates lysine residues in collagen telopeptides, a post-
translational modification required for the formation of stabi-
lized cross-links. PLOD2 expression is induced by hypoxia and
transforming growth factor-1 (TGF-1), well-known stimuli
for the formation of a fibrotic ECM, which can lead to patholog-
ical fibrosis underlying several diseases. Here, using human and
murine fibroblasts, we studied the molecular determinants
underlying hypoxia– and TGF-1–induced PLOD2 expression
and its impact on collagen biosynthesis. Deletion mapping and
mutagenesis analysis identified specific binding sites for hypox-
ia-inducible factors (HIF) and TGF-1–activated SMAD pro-
teins on the human PLOD2 gene promoter that were required
for these stimuli to induce PLOD2 expression. Interestingly, our
experiments also revealed that HIF signaling plays a preponder-
ant role in the SMAD pathway, as intact HIF sites were abso-
lutely required for TGF-1 to exert its effect on SMAD-binding
sites. We also found that silencing PLOD2 expression did not
alter soluble collagen accumulation in the extracellular
medium, but it effectively abolished the deposition into the
insoluble collagen matrix. Taken together, our findings reveal
the existence of a hierarchical relationship between the HIF and
SMAD signaling pathways for hypoxia– and TGF-1–mediated
regulation of PLOD2 expression, a key event in the deposition of
collagen into the ECM.
Collagens represent a large family of extracellular matrix
(ECM)2 proteins that play an essential role in providing the
structural and biomechanical integrity of different tissues. 28
types of collagens (I–XXVIII) have been described in verte-
brates, which are divided into several families, the most impor-
tant being fibrillar collagens (I–III, V, XI, XXIV, and XXVII)
and basement membrane–forming collagen IV (1). Fibrillar
collagens form homotrimeric (three identical -chains) or het-
erotrimeric (two or three distinct polypeptide chains) mole-
cules, each -chain consisting of a major uninterrupted triple-
helical or collagenous domain characterized by repeating
sequences (GXY), flanked by noncollagenous domains at N and
C termini (2).
One of the prevalent features of collagen is its extensive post-
translational modifications, most of which are unique to colla-
gen protein (3). Among the reactions occurring intracellularly,
the hydroxylation of specific proline and lysine residues is crit-
ical for the structural integrity of the ECM (4). These reactions,
which occur before the formation of the triple helix, are cata-
lyzed by prolyl and lysyl hydroxylases, enzymes that reside in
the endoplasmic reticulum and require Fe2, 2-oxoglutarate,
O2, and ascorbate for their activity. In contrast to proline hy-
droxylation, described to be invariable among several types of
collagen in different tissues, the extent of lysyl hydroxylation
can vary significantly, depending on the collagen form, the
domain where it takes place, the tissue considered, and even the
pathophysiological conditions (5). This variable behavior actu-
ally comes from the fact that different enzymatic systems con-
tribute to this post-translational modification. Three isoforms
of lysyl hydroxylases (LH; EC 1.14.11.4), also known as procol-
lagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD), have been
described in vertebrates: LH1, LH2, and LH3, encoded by
PLOD1, PLOD2, and PLOD3 genes, respectively (6 –9). Genetic
diseases resulting from defects in these genes have provided
valuable information about their biological role. Thus, human
mutations in PLOD1 causes Ehlers–Danlos syndrome (EDS)
type VIA, a connective tissue disease characterized by hyper-
mobile joints, hyperextensible skin, and kyphoscoliosis (10).
EDS-VIA patients show a decreased level of hydroxylation in
the triple helix of collagen I and III, particularly in lysines
involved in cross-linking, indicating that LH1 uses these resi-
dues as preferential substrates (11). LH3 also hydroxylates
lysines in the helical region, but mostly of collagen types II, IV,
and V (12). In fact, LH3 is a multifunctional enzyme possessing
LH, galactosyltransferase, and glucosyltransferase activities,
which are sequentially required for the formation of glucosyl-
galactosyl hydroxylysines in collagens (13). Here again, muta-
tions in the LH3-coding gene, PLOD3, have been described that
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result in the development of severe malformations in multiple
tissues and organs, showing many features in common with
collagen disorders (14). LH2, for which two alternatively spliced
forms were identified, seems to be the genuine LH form
hydroxylating lysines in the nonhelical terminal peptides (telo-
peptides) (9, 15). Lysine and hydroxylysines in collagen telopep-
tides are substrates for lysyl oxidase, and the resulting alde-
hydes react with helical lysine or hydroxylysine residues to form
covalent cross-links (16, 17). In fact, the biological significance
of telopeptide hydroxylation is fundamental, as it impacts the
mechanical properties of the collagen network (18). When the
use of hydroxylysine over lysine is favored, instead of following
the allysine pathway, cross-linking proceeds through the
hydroxyallysine route, resulting in enhanced levels of pyridino-
line cross-links and, thereby, in a stiffer collagen matrix (19).
Strong evidence indicates that LH2 (PLOD2) is the only form
determining the formation of stabilized cross-links, as exempli-
fied by Bruck syndrome type 2, a heritable disorder in the osteo-
genesis imperfecta spectrum caused by mutations in the
PLOD2 gene and characterized by severe reduction or elimina-
tion of the telopeptide hydroxylysine-derived cross-links,
resulting in bone fragility (9). Therefore, it is important to
delineate the signaling pathway(s) regulating the expression of
PLOD2 as a way to understand the molecular mechanisms con-
tributing to tissue stiffness.
PLOD2 expression has been described to be strongly regu-
lated by transforming growth factor 1 (TGF-1) and hypoxia,
known stimuli for the synthesis and deposition of a fibrotic
ECM (20 –22). In this study, we analyzed the molecular deter-
minants for the induction of PLOD2 by hypoxia and TGF-1 in
fibroblasts as well as its impact on their capacity to promote
collagen synthesis and deposition. Our experiments identified
specific binding sites for hypoxia-inducible factors (HIF) and
TGF-–activated SMAD family members on the promoter
sequence of the human PLOD2 gene. Mutation analyses and
transcription factor overexpression assays further showed that
HIF proteins play a preponderant role in the induction of
PLOD2 expression, the action of these factors on their binding
site being an essential requirement for TGF-1 to exert its
effect on the SMAD-dependent sites. Finally, we demonstrate
that the expression of PLOD2 is fundamental for hypoxia and
TGF-1 to promote the deposition of collagen onto the insol-
uble collagen matrix, our findings providing novel knowledge
to understand the mechanisms leading to pathological fibrosis.
Results
Hypoxia and TGF-1 increase PLOD2 expression through a
transcriptionally mediated mechanism
The effect of lowering oxygen levels (hypoxia) and the stim-
ulation with TGF-1 on PLOD2 expression was investigated in
human lung fibroblast (CCD19-Lu) cells. As shown in Fig. 1 (A
and B), hypoxia caused an up-regulation in PLOD2 mRNA and
protein levels, and this action was further increased by incuba-
tion with TGF-1. As these human fibroblasts are difficult to
transfect, we analyzed the mechanism by which hypoxia and
TGF-1 induce PLOD2 expression in 3T3 mouse embryo
fibroblasts. An upstream regulatory sequence (1826/174) of
the human PLOD2 gene was cloned in front of a luciferase gene
to study whether the effect of hypoxia and TGF-1 occurs at the
transcriptional level (Fig. S1). Transient transfection of fibro-
blasts showed that the activity of this promoter fragment reca-
pitulated the behavior of the mRNA and protein (i.e. it was
up-regulated by the individual stimuli and further increased
when applied together) (Fig. 1C). These experiments indicate
that their action occurs at the transcriptional level and that the
promoter sequence contains the necessary information to
mediate the activation of the gene.
Hypoxia– and TGF-1–responsive elements in the human
PLOD2 promoter are responsible for the induction of PLOD2
expression
To identify hypoxia– and TGF-1–responsive elements
within the PLOD2 promoter fragment, we screened the 1826/
174 bp promoter region for putative binding sites for HIF and
SMAD proteins, both of which have been described to be
important for the effect of these stimuli on gene expression (23,
24) (Fig. S1). We then generated luciferase constructs under the
control of 5-deletional fragments based on the location of
these potential sites. Looking at the effect of hypoxia, Fig. 2
shows that the activity of the 1826/174 promoter fragment
was kept roughly intact until a putative HIF site at 230/226
was eliminated. For the effect of TGF-1, a much more com-
plex behavior was observed. Whereas a potentiation on basal
and hypoxia-induced conditions was observed for the parental
Figure 1. Hypoxia and TGF-1 induce PLOD2 expression and promoter activity in fibroblasts. A and B, quantitative PCR of PLOD2 mRNA and Western
blotting of PLOD2 protein from human lung fibroblasts treated under hypoxia or normoxia in the absence (basal) or presence of TGF-1 for 24 h. Housekeeping
-actin protein was also probed by Western blotting for normalization purposes. Numbers above the blot represent the signal ratio PLOD2/-actin upon
densitometric analysis. Data are mean  S.D. (error bars) (n  6): **, p  0.01 versus normoxia; *, p  0.05 versus basal. C, PLOD2 gene promoter (1826/174)
activation as assessed by luciferase reporter in mouse 3T3 fibroblasts treated with TGF-1 or basal under normoxic or hypoxic conditions. Data are mean  S.D.
(n  6): **, p  0.05; *, p  0.05. Statistical comparisons between groups were calculated by one-way ANOVA followed by Bonferroni’s post-test.
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1826 promoter fragment, the effect on basal activity lost sig-
nificance in constructs of 1260, 626, and 346, whereas it
was still evident under hypoxic conditions. Deletions up to
296 and further downstream were irresponsive to TGF-1.
Taken together, these results suggest the existence of a well-
defined HIF site in the PLOD2 promoter, whereas they reveal a
high complexity in the effect of TGF-1, likely reflecting the
action on multiple sites.
Careful inspection of the putative HIF site indicates a perfect
match with the HIF-binding CGTG (complementary strand
CACG in the PLOD2 gene) motif commonly found in a number
of hypoxia-responsive genes (25) (Fig. 3A). Interestingly, a HIF
ancillary sequence (HAS) of the form CACGC (GCGTG in the
PLOD2 gene) was also identified. HAS motifs are often found
between positions 13 and 15 with respect to the HIF sites
and shown to regulate their response to hypoxia (26). Multiple-
sequence alignment analysis of this region among several mam-
malian orthologs of PLOD2 revealed that both HAS and HIF
sites were evolutionarily conserved, suggesting functionality in
these genomes. In fact, mutation of these sites in the context of
the full promoter construct (1826/174) abolished the effect
of hypoxia and the potentiation by TGF-1 (Fig. 3B). To dem-
onstrate the absolute requirement of intact HAS and HIF sites
for hypoxia to induce PLOD2 promoter activity, constitutively
active forms of HIF1 and HIF2 were cotransfected with the
promoter constructs, and luciferase activity was analyzed by
luminometry. As shown in Fig. 4, HIF1 and HIF2 overexpres-
sion caused a strong potentiation of the effect of hypoxia in the
WT form, but not in the mutant constructs that behaved simi-
larly to the deletion 226/174. Again, the effect of TGF-1
was abolished in these mutant constructs. These results indi-
cate that both HAS and HIF elements are essential for the
hypoxia response and mediate the action of HIF factors. Addi-
tionally, intact HIF elements seem to be also required for
TGF-1 to induce PLOD2 transcription.
Despite structural and functional similarities, HIF1 and HIF2
exhibit remarkable differences in their transcriptional pro-
grams in response to hypoxia (27, 28). HIF1- and HIF2-depen-
dent responses can be mounted in vitro with reporter gene
assays that are not observed on endogenous target genes (29).
To investigate the contribution of HIF1 and HIF2 on PLOD2
expression, we have generated stable transfectants of human
embryonic kidney 293 (HEK293) cells overexpressing constitu-
tively active forms of HIF1 and HIF2 (N-terminally HA-tagged)
in a tetracycline-inducible manner. As shown in Fig. 5A, incu-
bation of these cell clones with the tetracycline analog, doxycy-
cline, induced the expression of these HIF forms, as assessed by
Western blotting using an anti-HA antibody. Cell transfection
with PLOD2 promoter-luciferase reporter and subsequent
induction of HIF expression gave rise to significant increases in
the luciferase activity, which were of a magnitude similar to
those induced by hypoxia in untransfected HEK293 cells (Fig.
5B). Therefore, as observed in fibroblasts, HIF1- and HIF2-
driven responses on PLOD2 expression can be recapitulated
using reporter gene assays in these cells. Interestingly, HIF1 and
HIF2 also induced the endogenous expression of PLOD2
mRNA and protein (Fig. 5, C and D). Again, these actions,
which were found to be higher with HIF2 than with HIF1, were
in the same range of those observed upon hypoxic incubation of
untransfected HEK293 cells. Additionally, we have performed
knockdown experiments to determine the contribution of HIF1
and HIF2 forms to the effect of hypoxia on PLOD2 expression
in fibroblasts. As shown in Fig. 6A, cell transfection with human
specific siRNA for HIF1 and HIF2 diminished the mRNA levels
of its corresponding HIF form, without significantly affecting
the other. Under these conditions, HIF1 or HIF2 siRNA did not
modify hypoxic induction of PLOD2 (Fig. 6B, left). As func-
tional redundancy may be operating for the effect of both iso-
forms, we set additional experiments with a combination of
HIF1/HIF2 siRNA. Using this approach, we observed a clear
reduction of the capacity of hypoxia to induce the expression of
PLOD2 (Fig. 6B, right). Taken together, our results indicate that
both HIF1 and HIF2 are fully competent in activating the
endogenous expression of PLOD2 and that both HIF forms play
redundant roles in the induction of this gene in response to
hypoxia.
Figure 2. Mapping of hypoxia– and TGF-1–responsive elements within the PLOD2 promoter. A and B, hypoxia– and TGF-1– dependent activity of
luciferase constructs driven by 5-deletional fragments of the PLOD2 promoter transfected into mouse 3T3 fibroblasts. A, schematic representation of the 1826
to 174 promoter sequence showing the position of putative HIF and SMAD sites (red and blue arrowheads, respectively). B, PLOD2 promoter activity as
assessed by luminometry. Data are mean  S.D. (error bars) (n  6): **, p  0.01; *, p  0.05. Statistical comparisons between groups were calculated by one-way
ANOVA followed by Bonferroni’s post-test.
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We have also investigated whether HIF factors bind to the
PLOD2 promoter. For this purpose, we have taken advantage of
the HEK293 clone overexpressing HA-tagged HIF1 in ChIP
experiments. As shown in Fig. 7A, incubation of HIF1 cell clone
with doxycycline promoted the accumulation in both cytosolic
and nuclear compartments of HA-tagged HIF1 protein. Fig. 7B
also shows that nuclear HIF1 can be efficiently immunoprecipi-
tated with an anti-HA antibody, a requisite for its performance
in ChIP assays. Using a primer pair targeting a PLOD2 genomic
sequence adjacent to the HIF-binding site, a significant enrich-
ment for HA-HIF1 was detected in cells treated with doxycy-
cline as compared with those under basal conditions (Fig. 7, C
and D). These results support our findings that induction of
PLOD2 expression is mediated by transcriptionally active HIF
factor. The binding of HIF2 could not be investigated, as the
anti-HA antibody failed to immunoprecipitate this HIF form
(data not shown).
Our experiments showed an absolute requirement of a func-
tional HIF site for TGF-1 to exert its action on PLOD2 expres-
sion. To analyze the molecular basis of this behavior, we
Figure 3. Characterization of HIF site and HAS within the PLOD2 promoter. A and B, specific point mutations that alter HIF and HAS sites as indicated were
introduced in the 1826/174 promoter, and the effect of hypoxia and TGF-1 was analyzed in mouse fibroblasts. A, schematic representation of the proximal
promoter region showing the location of HIF and HAS sites and multiple-sequence alignment analysis of this region among several mammalian orthologs.
Mutations introduced are shown in red. B, PLOD2 promoter activity as assessed by luminometry. Data are mean  S.D. (error bars) (n  6): **, p  0.01; *, p  0.05.
Statistical comparisons between groups were calculated by one-way ANOVA followed by Bonferroni’s post-test.
Figure 4. Involvement of HIF factors in the effect of hypoxia and TGF-1
on PLOD2 expression. Luciferase activity of 1826/174 WT, HIF/HAS
mutant, and 226/174 PLOD2 promoter constructs cotransfected with
constitutively active forms of HIF1 and HIF2 in hypoxia– and TGF-1–treated
mouse fibroblasts. Data are mean  S.D. (error bars) (n  6): **, p  0.01; *, p 
0.05. Statistical comparisons between groups were calculated by one-way
ANOVA followed by Bonferroni’s post-test.
Figure 5. Both HIF1 and HIF2 are capable of up-regulating PLOD2 expres-
sion. Stable transfectants of HEK293 cells were generated that overexpress
constitutively active, HA-tagged forms of HIF1 and HIF2 in a tetracycline-
inducible manner. A, HA-HIF1 and HIF2 expression in cell extracts was
assessed by Western blotting under basal conditions and upon induction
with the tetracycline analogue, Dox. B, PLOD2 promoter activity assessed by
reporter gene assays; C, PLOD2 mRNA quantified by quantitative PCR; D,
PLOD2 protein analyzed by Western blotting in cells left under basal condi-
tions or overexpressing HIF1 or HIF2. For comparison, the effect of hypoxia on
untransfected HEK293 cells is also shown. The expression of the housekeep-
ing -actin protein was also probed by Western blotting for even loading and
normalization purposes. Numbers above the blots represent the signal ratio
PLOD2/-actin upon densitometric analysis. Data are mean  S.D. (error bars)
(n  3): *, p  0.05. Statistical comparisons between groups were calculated
using unpaired t test.
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cotransfected a vector for the overexpression of SMAD3
together with a series of deletion constructs of PLOD2 pro-
moter based on the location of potential TGF-1–responsive
SMAD elements. As shown in Fig. 8, basal and TGF-1–
stimulated activities were strongly amplified by overexpression
of SMAD3 in the parental 1826 promoter fragment. A similar
effect, but much more attenuated, was observed for constructs
1260 and 346, whereas downstream fragments remained
unmodified. Therefore, the use of this approach revealed the
existence of two distinct TGF-1–responsive elements within
the PLOD2 promoter, a distal SMAD site of the form CAGAC
at position 1405/1401 and a proximal region with two
closely located CAGAC motifs at 337/333 and 313/309
(Fig. 9A). Mutant constructs altering these SMAD sites were
tested under overexpression of SMAD3 or mock. Fig. 9B shows
that the potentiation observed in the WT promoter was
strongly diminished in the vectors harboring these mutations
either individually or combined, these results indicating the
absolute requirement of both DNA regions for a full response to
TGF-1. Remarkably, multiple-sequence alignment showed
that, except for one proximal CAGAC site present in the rabbit
and bovine genomes, full conservation of these SMAD sites was
only found in hominidae, an observation that predicts that the
PLOD2 gene may not respond to TGF-1 in mammalian spe-
cies other than this family.
Hypoxia-inducible factors play a preeminent role in the
functional cooperation between HIF and SMAD proteins that
controls PLOD2 expression
Our results so far have revealed the existence of hypoxia–
and TGF-1–responsive elements within the PLOD2 promoter
and suggested a coordinated regulation for the induction of the
gene by these stimuli. To get deep into this potential mecha-
nism, we performed overexpression experiments with HIF1,
HIF2, and SMAD3 using constructs with mutations in HIF and
SMAD sites. As shown in Fig. 10A, combination of SMAD3
with HIF1 or HIF2 gave rise to a potentiation of the reporter
activity in the WT promoter fragment, which was further
increased by incubation with TGF-1. However, a construct
mutated in the HIF site, displaying a drastic reduction in the
capacity of HIF1/HIF2 to activate transcription, proved incapa-
ble of responding to SMAD3 in the absence or presence of
TGF-1. On the contrary, the promoter fragment with muta-
tions in the SMAD sites, irresponsive to SMAD3 overexpres-
sion or TGF-1 incubation, displayed strong increases by HIF1
and HIF2. In a similar behavior, the mutant in the SMAD sites
was still up-regulated by hypoxia, whereas the HIF mutant, as
shown above, did not respond to TGF-1 (Fig. 10B). These
results indicate a functional hierarchy in the action of both
transcription factors on PLOD2 promoter, with HIF factors
dominating the effect of TGF-1–stimulated SMAD proteins.
PLOD2 expression is required for the effect of hypoxia/TGF-1
on collagen deposition from fibroblast cultures
TGF-1 and hypoxia have been widely reported to contrib-
ute to collagen synthesis and deposition in different cell and
tissue models (24, 30-32). Nevertheless, the involvement of
PLOD2 in this action is poorly understood. To determine
whether this profibrotic effect requires PLOD2, we have
silenced the expression of this gene by siRNA technology in
Figure 6. siRNA-mediated down-regulation of HIF1 and HIF2 reduces PLOD2 expression induced by hypoxia in lung fibroblasts. A, HIF1 and HIF2 mRNA
assessed by quantitative PCR in cells transfected with HIF1, HIF2, and nontargeting (control) siRNA. Data are mean  S.D. (error bars) (n  6): *, p  0.05.
Statistical comparisons between groups were calculated by one-way ANOVA followed by Bonferroni’s post-test. B, PLOD2 protein expression was analyzed by
Western blotting in cells transfected with control (nontargeting) or HIF1 and HIF2 siRNA, either individually (left) or administered together (right) and treated
for 48 h under normoxia or hypoxia. Housekeeping -actin protein was also probed for normalization purposes. Numbers above the blot represent the signal
ratio PLOD2/-actin upon densitometric analysis.
Figure 7. Binding of HIF1 to PLOD2 proximal promoter. ChIP experiments
of binding of HA-tagged HIF1 to PLOD2 promoter. A, Western blot analysis of
cytosolic and nuclear fractions of stable transfectants of HA-HIF1 HEK293 cells
incubated in the absence (Basal) or presence of doxycycline (Dox). B, immu-
noprecipitation (IP) assays of nuclear extracts shown in A with anti-HA anti-
body coupled to Protein A/G-agarose beads. C, ChIP assay showing the bind-
ing of HA-HIF1 to PLOD2 promoter. Data are mean  S.D. (error bars) (n  3):
*, p  0.01. Statistical comparisons between groups were calculated using
unpaired t test. D, schematic representation of the position of ChIP amplifica-
tion quantitative PCR product within the PLOD2 genomic sequence.
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CCD-19Lu fibroblasts. As opposed to siRNA control, Fig. 11A
shows that siRNA PLOD2 abolished hypoxia– and TGF-1–
induced up-regulation of the gene. Having proved the perfor-
mance of these siRNA molecules, we have then studied the
effect of hypoxia and TGF-1 on collagen expression in
siRNA-transfected cells. First, we performed immunofluores-
cence analyses with an anti-collagen type I, 1 chain (col11)
antibody (Fig. S2). As shown in Fig. S2, faint col11-im-
munoreactive aggregates were observed in control siRNA-
transfected fibroblasts under normoxic conditions that became
enlarged and more intense upon incubation with hypoxia/
TGF-1. In contrast, PLOD2-silenced fibroblasts displayed a
more diffuse staining that was not significantly modified in cells
incubated under hypoxia/TGF-1. Biochemical studies were
also done to analyze the various collagen fractions representing
the sequential steps in the biosynthetic process. As shown in
Fig. 11B, cells exposed to hypoxia and TGF-1 for 4 days accu-
mulated in the supernatants higher levels of the soluble form of
secreted collagen than those incubated under basal conditions,
and no differences were observed in control versus PLOD2
siRNA. In contrast, compared with control, PLOD2 siRNA sig-
nificantly reduced TGF-1/hypoxia–induced increase in the
levels of pepsin-soluble collagen extracted from cell layers, a
fraction that reflects recently cross-linked collagen (Fig. 11C).
Under our experimental conditions, cells accumulated very
small amounts of pepsin-insoluble collagen, and these were not
modified by PLOD2 siRNA (data not shown). Taken together,
these results demonstrate an important role for PLOD2 in the
effect of hypoxia and TGF-1 on collagen biosynthesis, specif-
ically affecting the process of its deposition on the extracellular
matrix.
Discussion
The ECM constitutes a collection of macromolecules pro-
duced and secreted by cells into the surrounding medium that
not only provides structural support but also influences a num-
ber of cellular processes, including cell proliferation, adhesion,
migration, and differentiation (33). Proper synthesis and
assembly of the components of the ECM is essential for cell and
tissue homeostasis, and therefore, defects or alterations in these
processes are associated with the development of several
human disorders. Fibrosis, the aberrant accumulation of ECM
components, mainly collagens, is the hallmark of a number of
chronic diseases, such as idiopathic pulmonary fibrosis or liver
Figure 8. SMAD3 overexpression reveals the existence of two distinct TGF-1–responsive elements within the PLOD2 promoter. A and B, luciferase
activity of 5-deletional fragments of the PLOD2 promoter cotransfected with SMAD3 in mouse fibroblasts treated with TGF-1 or vehicle. A, schematic
representation of the 1826 to 174 promoter sequence showing the position of putative SMAD sites (blue arrowheads). B, PLOD2 promoter activity as
assessed by luminometry. Data are mean  S.D. (error bars) (n  6): **, p  0.01; *, p  0.05. Statistical comparisons between groups were calculated by one-way
ANOVA followed by Bonferroni’s post-test.
Figure 9. Characterization of TGF-1–activated SMAD sites within the PLOD2 promoter. A and B, specific point mutations that alter SMAD sites as
indicated were introduced in the 1826/174 promoter, and the effect of SMAD3 overexpression and TGF-1 was analyzed in mouse fibroblasts. A, schematic
representation of the promoter region showing the location of SMAD sites and multiple-sequence alignment analysis of these regions among several mam-
malian orthologs. Mutations introduced are shown in red. B, PLOD2 promoter activity as assessed by luminometry. Data are mean  S.D. (error bars) (n  6): **,
p  0.01; *, p  0.05. Statistical comparisons between groups were calculated by one-way ANOVA followed by Bonferroni’s post-test.
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cirrhosis, among others (34). TGF-1 and hypoxic conditions
have been widely reported as drivers of fibrosis due to their
capacity to increase the expression of matrix components and
matrix-remodeling enzymes, including procollagen prolyl and
lysyl hydroxylases (20 –22, 30 –32, 35). Confirming previous
observations reporting the capacity of TGF-1 and hypoxia to
individually induce the expression of PLOD2, here we show
that both stimuli functionally interact to promote the expres-
sion of this gene (20, 21). Our experiments identified specific
binding sites for HIF and SMAD transcription factors on the
promoter of human PLOD2, implying the activation of HIF-
and SMAD-dependent signaling pathways in the induction of
the gene. As to the HIF site, whereas genome-wide studies have
previously detected the binding of this transcription factor in
the vicinity of the PLOD2 proximal promoter, our analysis pro-
vided the specific location of this site as well as of its cognate
HIF ancillary sequence, demonstrating their functionality (25,
27, 36, 37). We also report here that both HIF1 and HIF2 are
fully competent and functionally redundant in activating the
expression of PLOD2, a result that is in agreement with previ-
ous studies showing that both HIF forms exert a strong influ-
ence on the expression of ECM remodeling enzymes in endo-
thelial cells (27). In fact, HIF2, which has been traditionally
considered to be expressed exclusively in this cell type, is also
found in fibroblasts and other cells of mesenchymal phenotype,
as can be visualized in a recent single-cell transcriptomic anal-
ysis of mouse organs (38). Therefore, HIF2, together with the
ubiquitously expressed HIF1, can significantly contribute to the
fibrotic response to hypoxia. With respect to the effect of TGF-
1, previous studies have identified SMAD2/3-binding regions
in the PLOD2 locus in HepG2 hepatoblastoma cells and HaCaT
epidermal keratinocytes (39). Similarly, the work by Gjaltema et
al. (21) demonstrated binding of SMAD3 to PLOD2 promoter,
in this case restricted to the transcriptional start site, rather
than at upstream regions. Our studies add to this evidences by
unequivocally locating the binding sites for SMAD factors
along the PLOD2 promoter. In fact, a remarkable complexity in
the manner in which these factors interact with DNA is sug-
gested, as their action requires cooperativity between two inde-
pendent upstream and downstream locations. Interestingly,
our studies also revealed a functional hierarchy in the induction
of PLOD2 promoter by activation of HIF and SMAD signaling
Figure 10. HIF signaling dominates over SMAD pathway in regulating
PLOD2 expression. A and B, luciferase activity of 1826/174 WT, HIF, and
SMAD mutant PLOD2 promoter constructs cotransfected with HIF1, HIF2, and
SMAD3 overexpression plasmids in mouse fibroblasts. PLOD2 promoter activity
upon cotransfection of SMAD3 with HIF1/2 plasmids (A) or under normoxia/hy-
poxia (B) in cells treated with TGF-1 or basal. Data are mean  S.D. (error bars)
(n  6): **, p  0.01; *, p  0.05. Statistical comparisons between groups were
calculated by one-way ANOVA followed by Bonferroni’s post-test.
Figure 11. siRNA-mediated down-regulation of PLOD2 reduces collagen
deposition in human lung fibroblasts treated with hypoxia and TGF-1.
A, PLOD2 protein expression assessed by Western blotting in cells transfected
with PLOD2 or nontargeting (control) siRNA and treated for 48 h with hypox-
ia/TGF-1 or basal. Housekeeping -actin protein was also probed by West-
ern blotting for normalization purposes. Numbers above the blot represent
the signal ratio PLOD2/-actin upon densitometric analysis. Collagen frac-
tions were analyzed in fibroblasts transfected with PLOD2 or control siRNA
and incubated under basal conditions or with hypoxia/TGF-1 for 4 days:
soluble collagen in the supernatant (B) or pepsin-solubilized collagen fraction
associated with cell monolayer (C). Data are mean  S.D. (error bars) (n  6):
**, p  0.01; *, p  0.05. Statistical comparisons between groups were calcu-
lated by one-way ANOVA followed by Bonferroni’s post-test.
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pathways, with HIF proteins dominating the effect of TGF-1–
stimulated SMAD factors. In this respect, a direct interaction
between HIF and SMAD factors has been described previously
as being established at genes activated by TGF-1 and hypoxia,
such as endoglin or vascular endothelial growth factor (40, 41).
Interestingly, here we observed that the disruption of the HIF
site abolished the capacity of TGF-1 or overexpressed
SMAD3 to activate the PLOD2 promoter even in normoxic
conditions, suggesting site occupancy by HIF or another hith-
erto unidentified transcription factor utilizing this site under
normoxia. In this line, a certain extent of occupancy of HIF sites
by HIF factors in normoxia has been revealed previously by
ChIP methodology for several HIF-regulated genes, including
PLOD2 (37, 42, 43) (ArrayExpress accession number E-GEOD-
81635). It is at present unknown which molecular determinants
facilitate the normoxic stabilization of HIF factors on certain
promoter-binding sites.
Our data also show that the induction of the expression of
PLOD2 is fundamental for TGF-1 and hypoxia to promote the
deposition of collagen into the insoluble ECM. Specifically, the
abrogation of PLOD2 expression impaired the accumulation of
pepsin-soluble collagen extracted from cell layers, a fraction
representing recently cross-linked collagen, whereas it did not
modify the accumulation of the soluble form in the conditioned
medium. This observation is consistent with the role of PLOD2
as an important determinant of the formation of stabilized
cross-links, as demonstrated in models of tumor stroma and
fibrosis (18, 19). These pieces of knowledge support the devel-
opment of inhibitors of LH2/PLOD2 as a therapeutic approach
to treat these diseases, together with inhibitors of lysyl oxidases,
the enzymatic systems genuinely devoted to collagen cross-
linking (44, 45). Interestingly, the expression of the whole set of
procollagen prolyl and lysyl hydroxylases, as well as of the most
members of the lysyl oxidase family, has been described to be
induced by hypoxia, and this action has been shown to coordi-
nately mediate ECM remodeling (22, 35, 46, 47). All of these
enzymatic systems require molecular oxygen for the catalysis,
and, perhaps not surprisingly, their expression is exquisitely
regulated by hypoxic conditions. This observation, which is con-
sistent with the preponderant role of the axis hypoxia/HIF in
regulating PLOD2 expression, as evidenced in our work,
opposes the general underappreciation of hypoxia, when com-
pared with TGF-1, as a master regulator of collagen synthesis
and deposition.
In conclusion, our studies provide novel insights about the
molecular mechanisms by which hypoxia and TGF-1 regulate
the expression of PLOD2 as well as demonstrate an important
role of this gene in the deposition of collagen into the ECM,
both pieces of knowledge helping us to obtain a better molecu-




Fibroblast cell lines CCD-19Lu (human lung, CCL-210) and
NIH/3T3 (mouse embryonic, CRL-1658) were obtained from
ATCC (Manassas, VA) and maintained in culture using stan-
dard methods (48, 49). Tetracycline-inducible HEK293 cells
stably expressing constitutively active forms of human hypoxia
inducible factors HIF-1 and HIF-2 were generated and
maintained in culture according to protocols published previ-
ously (50).
RNA expression by quantitative PCR
For RNA experiments, CCD-19Lu fibroblasts were cultured
in 60-mm cell culture dishes and incubated at confluence in the
absence or presence of 5 ng/ml TGF-1 (R&D Systems, Min-
neapolis, MN) under normoxic or hypoxic conditions (1% oxy-
gen, H35 Hypoxystation, Don Whitley Scientific, West York-
shire, UK). Total RNA was extracted using the RNAeasy kit
(Qiagen, Hilde, Germany), the cDNA was synthesized (High
Capacity cDNA Reverse Transcription Kit, Applied Biosys-
tems, Foster City, CA), and quantitative real-time RT-PCR was
performed using iQ SYBR Green Supermix (Bio-Rad) and spe-
cific primers for human PLOD2, HIF1, and HIF2 (see Table S1)
in a CFX96 thermocycler (Bio-Rad). The mRNA expression of
the housekeeping gene hypoxanthine phosphoribosyltrans-
ferase 1 (HPRT) was determined using a TaqMan probe
(Hs01003267_m1) and TaqMan Fast Advance Master Mix
(Applied Biosystems) following the manufacturer’s instruc-
tions, and data normalization was performed with the Ct
method (51).
Western blotting analyses
For protein studies, CCD-19Lu fibroblasts were cultured in
100-mm cell culture dishes and processed essentially as
described previously (52). Briefly, cells were washed with PBS
and lysed with Tris-SDS buffer (60 mM Tris-HCl, pH 6.8, 2%
SDS) to obtain total cell lysate. Protein concentration was
determined by the BCATM protein assay kit (Thermo Scientific,
Rockford, IL). Even amounts of protein (30 g) were separated
on 10% SDS-polyacrylamide gels, and fractioned proteins were
transferred onto nitrocellulose membranes at 25 V for 20 min
in a semi-dry Trans-Blot Turbo system (Bio-Rad). Membranes
were blocked by incubation for 30 min with 1% BSA in PBS
containing 0.5% Tween 20, and antigens were detected using
specific primary antibodies (PLOD2: mouse polyclonal,
Abcam, Cambridge, UK; -actin: mouse monoclonal, Sigma;
hemagglutinin (HA) tag: Biolegend, San Diego, CA). Blots were
then incubated with the corresponding IRDye secondary
antibodies and detected using the Odyssey IR imaging system
(LI-COR, Lincoln, NE).
Construction of PLOD2 gene promoter reporter constructs and
cell transfection
Analysis of PLOD2 gene transcriptional activity was per-
formed by luciferase reporter gene studies using genomic
fragments of the PLOD2 gene. A human PLOD2 promoter frag-
ment (chr3: 146,160,994 –146,162,989, reverse strand, contain-
ing partial exon 1 and 5-flanking sequences up to position
1826 with respect to the transcription start site; Fig. S1) was
obtained as a clone in the vector pCpG-PLOD2-2000 (a gift
from Rutger A. F. Gjaltema and Ruud A. Bank, University of
Groningen, The Netherlands) (21). A pGL3-luciferase cas-
sette under the control of the PLOD2 promoter (pGL3-
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PLOD21826/174) was generated by insertion of this frag-
ment into pGL3-vector (Promega, Madison, WI) by standard
cloning procedures. Preliminary attempts to generate 5-dele-
tional fragments of the PLOD2 promoter based on Pfu-based
PCR using this construct were unsuccessful, likely due to the
presence of a high GC sequence in the proximal promoter.
Therefore, a shorter promoter construct was generated by re-
striction cutting at a 5-end SacI site in the vector and a 3-end
ApaI site in the promoter, right upstream of the GC-rich
sequence, and further religation to yield pGL3-PLOD2153/
174. The upstream promoter fragment (1826/154) was
subcloned into pCR2.1 vector (Invitrogen), and deletion frag-
ments thereof starting at positions ranging from 1826 to
154 were generated by Pfu-based PCR. They were then
excised by restriction cutting and cloned into pGL3-
PLOD2153/174 (upstream of the proximal promoter) to
yield the series of pGL3-PLOD2 constructs used in this study
(primers used shown in Table S2). Reporter luciferase con-
structs under the control of promoter fragments with specific
mutations in HIF and HAS sites, as well as in the SMAD-bind-
ing elements, were generated by PCR-based site-directed
mutagenesis within pCR2.1-PLOD21826/154 and then
assembled into the luciferase reporter-proximal promoter plas-
mid as described above (primers in Table S2). All constructs
were verified by sequencing.
The vectors expressing constitutively active forms of human
hypoxia-inducible factors HIF-1 (P402A/P564A-pcDNA3,
N-terminally HA-tagged) and HIF-2 (P405A/P531A-pcDNA3,
N-terminally HA-tagged) were a gift from William Kaelin
(Addgene plasmids 18955 and 18956) (53). The vector express-
ing SMAD3 transcription factors was kindly provided by Lili-
ana Attisano (Toronto, Canada).
DNA constructs were transiently transfected into 3T3 fibro-
blasts seeded on 24-well plates (60 –70% confluence), and pro-
moter activity was estimated by luminometry as described pre-
viously using pRL-CMV plasmid (a Renilla luciferase under the
control of the cytomegalovirus promoter) for normalization
purposes (52).
Sequence alignments for the identification of potential con-
served transcription factor– binding sites were performed with
Clustal Omega at the European Bioinformatics Institute
(EMBL-EBI). PLOD2 orthologous sequences from Mus muscu-
lus, Rattus norvegicus, Canis familiaris, Equus caballus, Oryc-
tolagus cuniculus, Bos taurus, Pan troglodytes, and Pongo pyg-
maeus were obtained from the ENSEMBL genome database.
ChIP
ChIP experiments were performed using a commercially
available kit (Abcam) according to the manufacturer’s instruc-
tions. Briefly, stable transfectants of HEK293 cells were treated
with doxycycline to induce the expression of HA-tagged HIF1
or left under vehicle. Afterward, they were trypsinized and
washed with PBS buffer and then resuspended for fixation in 1%
formaldehyde (Calbiochem). Glycine was added to quench the
excess of formaldehyde, and cells were washed with PBS, resus-
pended in lysis buffer, and sonicated using a Bioruptor system
(Diagenode, Liège, Belgium). After removal of a control aliquot
(input), sheared chromatin was incubated for 2 h at 4 °C with
mouse monoclonal anti-HA antibody (clone 12CA5) or nega-
tive control IgG. Protein A/G Plus-agarose beads were then
added, incubated for 2 h and extensively washed before chro-
matin was released by proteinase K digestion and DNA was
recovered using a DNA-purifying slurry. DNA was used for
amplification of a region of 108 bp in a location adjacent to the
HIF site by real-time quantitative PCR (see Table S3). ChIP data
were calculated as percentage of input after IgG background
subtraction.
siRNA-mediated inhibition of HIF1, HIF2, and PLOD2
expression
Specific siRNA for the inhibition of the expression of human
PLOD2, HIF1, HIF2, and nontargeting control was purchased
from Ambion (Silencer Select siRNA, negative control 1
siRNA, catalog no. 4390843; for PLOD2, see Table S4, Life
Technologies, Inc.). siRNA transfection in CCD-19Lu fibro-
blasts was performed with INTERFERin reagent (Polyplus,
Strasbourg, France), following the manufacturer’s instructions,
in 6-well plates and 100-mm cell culture dishes for immuno-
blotting and collagen analyses, respectively.
Collagen analysis
Collagen fractions were extracted from CCD-19Lu fibroblast
cultures that represent the sequential steps in the biosynthetic
process using a protocol described previously (54). Briefly, after
4 days of incubation under basal or hypoxia/TGF-1–
stimulated conditions, cell supernatants were collected, and
soluble collagen was measured upon concentration with a Sir-
col soluble collagen assay (Biocolor, Carrickfergus, UK) follow-
ing the manufacturer’s instructions. On the other hand, cell
layers were scraped and extracted overnight with acid-based
buffer (0.5 M acetic acid), and resulting pellets were digested
with 0.5 mg/ml pepsin (Sigma-Aldrich) in 10 mM HCl. Corre-
sponding solubilized fractions were analyzed for collagen with
Sircol. Insoluble collagen after pepsin digestion was hydrolyzed
at 100 °C for 16 h with 12 M HCl, neutralized with NaOH, and
analyzed by a hydroxyproline assay using hydrolyzed type I col-
lagen as a standard (55).
Fluorescence microscopy was performed as described previ-
ously (54). Briefly, cells were seeded onto 10-mm glass diameter
coverslips (no. 1.5) in 35-mm culture dishes (Mattek, Ashland,
MA). After the corresponding treatment, cells were fixed with
cold methanol for 5 min, blocked with 1% BSA in PBS for 1 h,
and then incubated overnight at 4 °C with anti-collagen 1 type
I antibody (Santa Cruz Biotechnology, Inc.), followed by the
corresponding fluorescent secondary antibody. Nuclear stain-
ing was performed with 4,6-diamidino-2-phenylindole. Fluo-
rescence was visualized by microscopy with a Nikon Eclipse
T2000U (Nikon, Amstelveen, The Netherlands).
Statistical analysis
Data are presented as the mean  S.D. of n independent
measurements as indicated in the corresponding figure leg-
ends. Statistical comparisons between groups were calculated
by one-way ANOVA followed by Bonferroni’s post-test for
multiple-group comparisons or with an unpaired t test in the
case of two samples using GraphPad Prism version 6. The p
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values obtained are indicated in the figure legends when statis-
tically significant (p  0.05).
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